Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Delgocitinib is an inhibitor of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2; IC50s = 2.8, 2.6, 13, and 58 nM, respectively).1 It is selective for JAK1, JAK2, JAK3, and TYK2 over lymphocyte cell-specific tyrosine kinase (LCK; IC50 = 5,800 nM). Delgocitinib inhibits IL-31-induced increases in STAT3 phosphorylation levels in A549 cells (IC50 = 25 nM). It reduces IL-31-induced scratching in mice in a dose-dependent manner.2 Formulations containing delgocitinib have been used in the treatment of atopic dermatitis.
WARNING This product is not for human or veterinary use.
1. Discovery of a Janus kinase inhibitor bearing a highly three-
2. Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model. J. Dermatol. Sci. 97(2), 161-164 (2020).